References

pulmo

Пульмонология

PULMONOLOGIYA

0869-01892541-9617

Scientific and Practical Journal “PULMONOLOGIYA” LLC

10.18093/0869-0189-2017-27-2-262-273

pulmo-849

Research Article

ОБЗОРЫ

REVIEW

Нитрозивный и оксидативный стресс при заболеваниях органов дыхания

Nitrosative and oxidative stresses in respiratory diseases

Соодаева

С. К.

Soodaeva

S. K.

soodaeva@mail.ru

Климанов

И. А.

Klimanov

I. A.

igorklimanov@yandex.ru

Никитина

Л. Ю.

Nikitina

L. Yu.

lidiya-nikitina@mail.ru

Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства России; Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М.Сеченова» Министерства здравоохранения Российской ФедерацииРоссияFederal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of RussiaRussian Federation

Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства РоссииРоссияFederal Pulmonology Research Institute, Federal Medical and Biological Agency of RussiaRussian Federation

Бюджетное учреждение высшего образования «Ханты-Мансийская государственная медицинская академия»РоссияKhanty-Mansiyskaya State Medical AcademyRussian Federation

2017

05072017

272262273

2017

Соодаева С.К., Климанов И.А., Никитина Л.Ю.

Soodaeva S.K., Klimanov I.A., Nikitina L.Y.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.pulmonology.ru/pulm/article/view/849

Заболевания органов дыхания сопровождаются интенсификацией свободнорадикальных процессов на разных уровнях биологической организации организма с одновременным напряжением и последующим угнетением различных звеньев антиоксидантной защиты, что приводит к развитию оксидативного (ОС) и нитрозивного (НС) стресса. Рассмотрены основные механизмы развития и инициации ОС и НС при патологии легких. Охарактеризованы системы антиоксидантной защиты респираторного тракта. Представлены результаты исследования маркеров НС и ОС при различных заболеваниях респираторного тракта. Показано, что НС и ОС являются многоуровневыми сложнорегулируемыми процессами, существующими и развивающимися в нераздельной связи с рядом физиологических и патофизиологических процессов. Изучение механизмов НС и ОС способствует улучшению качества диагностики и побуждает к разработке новых терапевтических подходов и агентов, воздействующих на отдельные звенья патогенеза.

Respiratory diseases are accompanied by activation of free radical-related processes with enhancement and subsequent suppression of different parts of antioxidant defense. This could result in development of oxidative and nitrosative stresses. General mechanisms of development of oxidative and nitrosative stresses in respiratory diseases as well as antioxidant defense of respiratory system have been described in this review. Markers of oxidative and nitrosative stresses in different respiratory pathology were investigated. Oxidative and nitrosative stresses are multi-level processes with intricate regulation which are closely related to other physiological and pathophysiological processes. Investigation of mechanisms of oxidative and nitrosative stresses could improve diagnostics and contribute to development of new therapeutic approaches and agents.

нитрозивный и оксидативный стресссвободнорадикальные процессыактивные формы кислородаактивные формы азотасистемы антиоксидантной защитыметаболиты оксида азотаконденсат выдыхаемого воздухахроническая обструктивная болезнь легкихантиоксидантная терапия

oxidative and nitrosative stressesfree radical processesreactive oxygen speciesreactive nitrogen speciesantioxidant defensenitric oxide metabolitesexhaled breath condensatechronic obstructive pulmonary diseaseantioxidant therapy

References1

Ricciardolo F.L.M., Caramori G., Ito K. et al. Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2005; 116 (5): 1028–1035. DOI: 10.1016/j.jaci.2005.06.034.

Соодаева С.К. Свободнорадикальные механизмы повреждения при болезнях органов дыхания. Пульмонология. 2012; (1): 5–10.

Soodaeva S.K. Free radical injury in respiratory diseases. Pul'monologiya. 2012; (1): 5–10 (in Russian).

Sugiura H., Ichinose M. Nitrative stress in inflammatory lung diseases. Nitric Oxide. 2011; 25 (2): 138–144. DOI: 10.1016/j.niox.2011.03.079.

Dozor A.J. The role of oxidative stress in the pathogenesis and treatment of asthma. Ann. New York Academy of Sciences. 2010; 1203: 133–137. DOI: 10.1111/j.17496632.2010.05562.x.

Dozor A.J. The role of oxidative stress in the pathogenesis and treatment of asthma. Ann. New York Academy of Sciences. 2010; 1203: 133–137. DOI: 10.1111/j.1749-6632.2010.05562.x.

Kirkham P.A., Barnes P.J. Oxidative stress in COPD. Chest. 2013; 144 (1): 266–273. DOI: 10.1378/chest.12-2664.

Antus B., Kardos Z. Oxidative stress in COPD: molecular background and clinical monitoring. Curr. Med. Chemistry. 2015; 22 (5): 627–650.

Соодаева С.К., Климанов И.А. Нарушения окислительного метаболизма при заболеваниях респираторного тракта и современные подходы к антиоксидантной терапии. Практическая пульмонология. 2009; (1): 34–38.

Soodaeva S.K., Klimanov I.A. Oxidative metabolism abnormalities in respiratory diseases and current approach to antioxidant therapy. Prakticheskaya pul'monologiya. 2009; (1): 34–38 (in Russian).

Соодаева С.К., Никитина Л.Ю., Климанов И.А. Механизмы развития оксидативного стресса под воздействием аэрополлютантов окружающей среды: потенциал средств антиоксидантной защиты. Пульмонология. 2015; 25 (6): 736–742. DOI: 10.18093/0869-0189-201525-6-736-742.

Soodaeva S.K., Nikitina L.Yu., Klimanov I.A. Mechanisms of oxidative stress caused by environmental air pollutants: antioxidative defence potential. Pul'monologiya. 2015; 25 (6): 736–742. DOI: 10.18093/0869-0189-2015-25-6-736742 (in Russian).

Berend N. Contribution of air pollution to COPD and small airway dysfunction. Respirology. 2016; 21 (2): 237–244. DOI: 10.1111/resp.12644.

BiaBas A.J., Sitarek P.B., Mibkowska-Dymanowska J. et al. The role of mitochondria and oxidative/antioxidative imbalance in pathobiology of chronic obstructive pulmonary disease. Oxid. Med. Cell. Long. 2016; 2016: 1–15. DOI: 10.1155/2016/7808576.

BiaBas A.J., Sitarek P.B., MiBkowska-Dymanowska J. et al. The role of mitochondria and oxidative/antioxidative imbalance in pathobiology of chronic obstructive pulmonary disease. Oxid. Med. Cell. Long. 2016; 2016: 1–15. DOI: 10.1155/2016/7808576.

Владимиров Ю.А. Физико-химические основы патологии клетки: Курс лекций. М.; 2001.

Vladimirov Yu.A. Physical and Chemical Basis of Cell Pathology. Lecture Course. Moscow; 2001 (in Russian).

Thomasi A., Ozden T., Sculachev V. Free radicals, nitric oxide, and inflammation: molecular, biochemical, and clinical aspects. In: NATO: Life and behavioural sciences. 344. Amsterdam: IOS Press; 2003: 71–88.

Соодаева С.К., Климанов И.А., Никитина Л.Ю. Особенности цикла оксида азота при респираторных заболеваниях. Пульмонология. 2016; 26 (6): 753–759. DOI: 10.18093/0869-0189-2016-26-6-753-759.

Soodaeva S.K., Klimanov I.A., Nikitina L.Yu. Particularities of nitric oxide cycle in respiratory diseases. Pul'mo- nologiya. 2016; 26 (6): 753–759. DOI: 10.18093/08690189-2016-26-6-753-759 (in Russian).

Ricciardolo F.L.M., Sterk P.J., Gaston B., Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol. Rev. 2004; 84 (3): 731–765. DOI: 10.1152/physrev.00034.2003.

Ricciardolo F.L. Multiple roles of nitric oxide in the airways. Thorax. 2003; 58 (2): 175–182.

Климанов И.А., Соодаева С.К. Механизмы формирования конденсата выдыхаемого воздуха и маркеры оксидативного стресса при патологиях респираторного тракта. Пульмонология. 2009; (2): 113–119.

Klimanov I.A., Soodaeva S.K. Mechanisms of exhaled breath condensate production and markers of oxidative stress in respiratory diseases. Pul'monologiya. 2009; (2): 113–119 (in Russian).

Hanazawa T., Kharitonov S., Barnes P.J. Increased nitrotyrosine in exhaled breath condensate of patients with asthma. Am. J. Respir. Crit. Care Med. 2000; 162 (4): 1273–1276. DOI: 10.1164/ajrccm.162.4.9912064.

Corradi M., Montuschi P., Donnelly L.E. et al. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. Am. J. Respir. Crit. Care Med. 2001; 163 (4): 854–858. DOI: 10.1164/ajrccm.163.4.2001108.

Malerba M., Radaeli A., Olivini A. et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed. Res. Int. 2014; 2014: 271918. DOI: 10.1155/2014/271918.

Formanek W., Inci D., Lauener R.P. et al. Elevated nitrite in breath condensates of children with respiratory disease. Eur. Respir. J. 2002; 19 (3): 487–491.

Ho L.P., Innes J.A., Greening A.P. Nitrite levels in breath condensate of patients with cystic fibrosis is elevated in contrast to exhaled nitric oxide. Thorax. 1998; 53 (8): 680–684.

Kharitonov S.A., Barnes P.J. Exhaled markers of inflammation. Curr. Opin. Allergy Clin. Immunol. 2001; 1 (3): 217–224.

McCafferty J.B., Bradshaw T.A., Tate S. et al. Effects of breathing pattern and inspired air conditions on breath condensate volume, pH, nitrite, and protein concentration. Thorax. 2004; 59: 694–698. DOI: 10.1136/thx.2003.016949.

Климанов И.А., Соодаева С.К., Лисица А.В. и др. Стандартизация преаналитического этапа исследования конденсата выдыхаемого воздуха. Пульмонология. 2006; (2): 53–55.

Klimanov I.A., Soodaeva S.K., Lisitsa A.V. et al. Standardization of preanalytic stage of investigation of exhaled breath condensate. Pul'monologiya. 2006; (2): 53–55 (in Russian).

Millar T., Kanczler J., Bodamyali T. et al. Nitric Oxide. Its generation, reactions and role in physiology. In: NATO Conference Proceedings. 2001; 10–11.

Latzin P., Griese M. Exhaled hydrogen peroxide, nitrite and nitric oxide in healthy children: decrease of hydrogen peroxide by atmospheric nitric oxide. Eur. J. Med. Res. 2002; 7 (8): 353–358.

Emelyanov A., Fedoseev G., Abulimity A. et al. Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients. Chest. 2001; 120 (4): 1136–1139.

Horvath I., Donnely L., Kiss A., Kharitonov S. Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Am. J. Respir. Crit. Care Med. 1998; 158 (4): 1042–1046. DOI: 10.1164/ajrccm.158.4.9710091.

Ferreira I.M., Mehdi S. Hazari R.I. et al. Exhaled Nitric Oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164 (6): 1012–1101. DOI: 10.1164/ajrccm.164.6.2012139.

Dekhuijzen P.N., Aben K.K., Dekker I. et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 154 (3, Pt 1): 813–816.

van Beurden W.J., Dekhuijzen P.N., Harff G.A. et al. Variability of exhaled hydrogen peroxide in stable COPD patients and matched healthy controls. Respiration. 2002; 69 (3): 211–216.

Loukides S., Horvath I., Wodehouse T. et al. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am. J. Respir. Crit. Care Med. 1998; 158 (3): 991–914. DOI: 10.1164/ajrccm.158.3.9710031.

Majewska E., Kasielski M., Luczynski R. et al. Elevated exhalation of hydrogen peroxide and thiobarbituric acid reactive substances in patients with community acquired pneumonia. Respir. Med. 2004; 98 (7): 669–976.

Szkudlarek U., Maria L., Kasielski M. et al. Exhaled hydrogen peroxide correlates with the release of reactive oxygen species by blood phagocytes in healthy subjects. Respir. Med. 2003; 97 (6): 718–725.

Antczak A., Nowak D., Bialasiewicz P. et al. Hydrogen peroxide in expired air condensate correlates positively with early steps of peripheral neutrophil activation in asthmatic patients. Arch. Immunol. Ther. Exp. (Warsz.). 1999; 47 (2): 119–126.

Ho L.P., Faccenda J., Innes J.A. et al. Expired hydrogen peroxide in breath condensate of cystic fibrosis patients. Eur. Respir. J. 1999; 13 (1): 103–106.

Новоселов В.И. Роль пероксиредоксинов при окислительном стрессе в органах дыхания. Пульмонология. 2012; (1): 83–87.

Novoselov V.I. A role of peroxiredoxins for oxidative stress in respiratory system. Pul'monologiya. 2012; (1): 83–87 (in Russian).

Варламова Е.Г., Гольтяев М.В., Новоселов С.В. и др. Характеристика некоторых представителей суперсемейства тиоловых оксидоредуктаз. Молекулярная биология. 2013; 47 (4): 568–582.

Varlamova E. G., Gol'tyaev M. V., Novoselov S. V. et al. Characteristics of several substances from thiol oxireductase superfamily. Molekulyarnaya biologiya. 2013; 47 (4): 568– 582 (in Russian).

Fridovich I. Superoxide radical and superoxide dismutases. Ann. Rev. Biochem. 1995; 64: 97–112. DOI: 10.1146/ annurev.bi.64.070195.000525.

Fridovich I. Superoxide radical and superoxide dismutases. Ann. Rev. Biochem. 1995; 64: 97–112. DOI: 10.1146/annurev.bi.64.070195.000525.

Tainer J.A., Getzoff E.D., Richardson J.S. et al. Structure and mechanism of copper, zinc superoxide dismutase. Nature. 1983; 306 (5940): 284–287.

Hart P.J., Balbirnie M.M., Ogihara N.L. et al. A structurebased mechanism for copper-zinc superoxide dismutase. Biochemistry. 1999; 38 (7): 2167–2178. DOI: 10.1021/bi982284u.

Borgstahl G.E., Parge H.E., Hickey M.J. et al. The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. Cell. 1992; 71 (1): 107–118. DOI: 10.1016/00928674(92)90270-M.

Gardner P.R., Raineri I., Epstein L.B. et al. Superoxide radical and iron modulate aconitase activity in mammalian cells. J. Biol. Chem. 1995; 270 (22): 13399–13405.

Chelikani P., Fita I., Loewen P.C. Diversity of structures and properties among catalases. Cell. Mol. Life Sci. 2004; 61 (2): 192–208. DOI: 10.1007/s00018-003-3206-5.

Arner E.S., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000; 267 (7): 6102–6109.

Deponte M., Urig S., Arscott L.D. et al. Mechanistic studies on a novel, highly potent gold-phosphole inhibitor of human glutathione reductase. J. Biol. Chem. 2005; 280: 20628–20637. DOI: 10.1074/jbc.M412519200.

Padayatty S.J., Katz A., Wang Y. et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J. Am. Coll. Nutr. 2003; 22 (1): 18–35.

Shigeoka S., Ishikawa T., Tamoi M. et al. Regulation and function of ascorbate peroxidase isoenzymes. J. Exp. Bot. 2002; 53 (372): 1305–1319.

Herrera E., Barbas C. Vitamin E: Action, metabolism and perspectives. J. Physiol. Biochem. 2001; 57 (1): 43–56.

Traber M.G., Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic. Biol. Med. 2007; 43 (1): 4–15. DOI: 10.1016/j.freeradbiomed.2007.03.024.

Kelly G.S. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 1998; 3 (2): 114–127.

Millea P.J. N-acetylcysteine: multiple clinical applications. Am. Fam. Physician. 2009; 80 (3): 265–269.

Boesgaard S., Nielsen-Kudsk J.E., Laursen J.B. et al. Thiols and nitrates: reevaluation of the thiol depletion theory of nitrate tolerance. Am. J. Cardiol. 1998; 81: 21A–29A.

Zafarullah M., Li W.Q., Sylvester J., Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 2003; 60 (1): 6–20.

Amini A., Masoumi-Moghaddam S., Ehteda A., Morris D.L. Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy. J. Exp. Clin. Cancer. Res. 2014; 33 (1): 92. DOI: 10.1186/s13046-014-0092-7.

Gurbuz A.K., Ozel A.M., Ozturk R. et al. Effect of N-acetyl cysteine on Helicobacter pylori. South. Med. J. 2005; 98 (Suppl. 11): 1095–1097. DOI: 10.1097/01.smj.0000182486.39913.da.

Feldman L., Efrati S., Eviatar E. et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007; 72 (3): 359–363. DOI: 10.1038/sj.ki.5002295.

Zhou J., Wang M., Sun Y. et al. Nitrate Increased Cucumber Tolerance to Fusarium Wilt by Regulating Fungal Toxin production and distribution. Toxins (Basel.). 2017; 9 (3): pii: E100. DOI: 10.3390/toxins9030100.

Tse H.N., Tseng C.Z.S. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 825–836. DOI: 10.2147/COPD.S51057.

Santus P., Corsico A., Solidoro P. et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD. 2014; 11 (6): 705–717. DOI: 10.3109/15412555.2014.898040.

Stav D., Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 2009; 136 (2): 381–386. DOI: 10.1378/chest.09-0421.

Stey C., Steurer J., Bachmann S. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000; 16 (2): 253–262.

The authors declare that there are no conflicts of interest present.